Author information:
(1)Adjuvant Research Group, School of Biochemistry and Immunology, Trinity 
Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, 
Ireland.
(2)Centre for Immunology and Microbial Disease, Albany Medical College, 47 New 
Scotland Avenue, MC 151, Albany, NY 12208, USA.
(3)Statens Serum Institut, Department of Infectious Disease Immunology, 
Artillerivej 5, 2300 Copenhagen S, Denmark.
(4)School of Biochemistry and Immunology and Trinity College Institute of 
Neuroscience, Trinity College Dublin, Dublin 2, D02 PN40, Ireland.
(5)Centre for Innate Immunity and Infectious Diseases, MIMR-PHI and Department 
of Molecular and Translational Sciences, Monash University, Clayton, VIC 3068, 
Australia.
(6)Program in Innate Immunity, Division of Infectious Diseases and Immunology, 
Department of Medicine, University of Massachusetts Medical School, Worcester, 
MA, 01605, USA; Centre of Molecular Inflammation Research, Department of Cancer 
Research and Molecular Medicine, Norwegian University of Science and Technology, 
7491 Trondheim, Norway.
(7)Viral Immune Evasion Group, School of Biochemistry and Immunology, Trinity 
Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, 
Ireland.
(8)Adjuvant Research Group, School of Biochemistry and Immunology, Trinity 
Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 PN40, 
Ireland; Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN) 
& Advanced Materials Bio-Engineering Research Centre (AMBER), Trinity College 
Dublin, Dublin 2, D02 PN40, Ireland. Electronic address: lavellee@tcd.ie.